drugset / Trial / NCT07811882
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
Timeline
- Start
- 2025-10-10
- Primary completion
- 2026-06-17
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Artemether | Small molecule | 80 mg | — |
| Subject | Cipargamin | Small molecule | — | Oral |
| Subject | INE963 | Small molecule | — | Oral |
| Comparator | lumefantrine | Small molecule | 480 mg | — |